Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
Sponsor: Cedars-Sinai Medical Center
This NA trial investigates Brain Cancer and is currently ongoing. Cedars-Sinai Medical Center leads this study, which shows 16 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
16 versions recorded-
Aug 2025 — Present [monthly]
Active Not Recruiting NA
-
Sep 2024 — Aug 2025 [monthly]
Active Not Recruiting NA
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting NA
-
Aug 2023 — Jul 2024 [monthly]
Active Not Recruiting NA
▶ Show 11 earlier versions
-
Sep 2022 — Aug 2023 [monthly]
Active Not Recruiting NA
-
Sep 2021 — Sep 2022 [monthly]
Active Not Recruiting NA
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting NA
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Oct 2019 — Aug 2020 [monthly]
Active Not Recruiting NA
-
Nov 2018 — Oct 2019 [monthly]
Active Not Recruiting NA
-
Oct 2018 — Nov 2018 [monthly]
Active Not Recruiting NA
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting NA
-
Feb 2018 — Jun 2018 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Feb 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Jun 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cedars-Sinai Medical Center
- Columbia University
- Memorial Sloan Kettering Cancer Center
- NovoCure Ltd.
- University of Cincinnati
- University of Colorado, Denver
- University of Miami
For direct contact, visit the study record on ClinicalTrials.gov .